Mohammad Zamanian

Ms. Mohammad Zamanian


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2024 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
MZMohammad Zamanian
Mohammad Zamanian
HAHashem O. Alsaab
Hashem O. Alsaab
MGMaryam Golmohammadi
Maryam Golmohammadi
AYAlexey Yumashev
Alexey Yumashev
AJAbeer Mhussan Jabba
Abeer Mhussan Jabba
SOSamuel Baker Obakiro
Samuel Baker Obakiro

21 December 2021 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
Supat ChupraditSupat Chupradit
Supat Chupradit
DBDmitry Bokov
Dmitry Bokov
MZMohammad Zamanian
Mohammad Zamanian
MHMahsa Heidari
Mahsa Heidari
EHElham Hakimizadeh
Elham Hakimizadeh

11 June 2024 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
MZMohammad Zamanian
Mohammad Zamanian
MGMaryam Golmohammadi
Maryam Golmohammadi
AYAlexey Yumashev
Alexey Yumashev
AHAhmed Hjazi
Ahmed Hjazi
MTMariam Alaa Toama
Mariam Alaa Toama
GMGervason Moriasi
Gervason Moriasi

17 June 2022 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
MZMohammad Zamanian
Mohammad Zamanian
NTNiloofar Taheri
Niloofar Taheri
MOMaria Jade Catalan Opulencia
Maria Jade Catalan Opulencia
DBDmitry Olegovich Bokov
Dmitry Olegovich Bokov
SASharif Y. Abdullaev
Sharif Y. Abdullaev
GBGholamreza Bazmandegan
Gholamreza Bazmandegan
Traumatic brain injury (TBI) is still a major cause of concern for public health, and out of all the trauma-related injuries, it makes the highest contribution to death and disability worldwide. Patients of TBI continue to suffer from brain injury through an intricate flow of primary and secondary injury events. However, when treatment is provided in a timely manner, there is a significant window of opportunity to avoid a few of the serious effects. Pioglitazone (PG), which has a neuroprotective impact and can decrease inflammation after TBI, activates peroxisome proliferator-activated receptor-gamma (PPARγ). The objective of the study is to examine the existing literature to assess the neuroprotective and anti-inflammatory impact of PG in TBI. It also discusses the part played by microglia and cytokines in TBI. According to the findings of this study, PG has the ability to enhance neurobehavior, decrease brain edema and neuronal injury following TBI. To achieve the protective impact of PG the following was required: (1) stimulating PPARγ; (2) decreasing oxidative stress; (3) decreasing nuclear factor kappa B (NF-κB), interleukin 6 (IL-6), interleukin-1β (IL-1β), cyclooxygenase-2 (COX-2), and C-C motif chemokine ligand 20 (CCL20) expression; (4) limiting the increase in the number of activated microglia; and (5) reducing mitochondrial dysfunction. The findings indicate that when PIG is used clinically, it may serve as a neuroprotective anti-inflammatory approach in TBI.

16 June 2023 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
MZMohammad Zamanian
Mohammad Zamanian
ASAfsaneh Soltani
Afsaneh Soltani
ZKZahra Khodarahmi
Zahra Khodarahmi
AAAmeer A. Alameri
Ameer A. Alameri
AAAthemar M. R. Alwan
Athemar M. R. Alwan
MAMahdieh Anoush
Mahdieh Anoush

2 September 2024 in Animal Models and Experimental Medicine
Verified
Journal Article
Open access
MGMaryam Golmohammadi
Maryam Golmohammadi
MZMohammad Zamanian
Mohammad Zamanian
AAAhmed Muzahem Al‐Ani
Ahmed Muzahem Al‐Ani
TJThaer L. Jabbar
Thaer L. Jabbar
AKAli Kamil Kareem
Ali Kamil Kareem
EHElham Hakimizadeh
Elham Hakimizadeh
Background: Breast cancer (BC) continues to be a significant global health issue, with a rising number of cases requiring ongoing research and innovation in treatment strategies. Curcumin (CUR), a natural compound derived from Curcuma longa, and similar compounds have shown potential in targeting the STAT3 signaling pathway, which plays a crucial role in BC progression.Aims: The aim of this study was to investigate the effects of curcumin and its analogues on BC based on cellular and molecular mechanisms.Materials & Methods: The literature search conducted for this study involved utilizing the Scopus, ScienceDirect, PubMed, and Google Scholar databases in order to identify pertinent articles.Results: This narrative review explores the potential of CUR and similar compounds in inhibiting STAT3 activation, thereby suppressing the proliferation of cancer cells, inducing apoptosis, and inhibiting metastasis. The review demonstrates that CUR directly inhibits the phosphorylation of STAT3, preventing its movement into the nucleus and its ability to bind to DNA, thereby hindering the survival and proliferation of cancer cells. CUR also enhances the effectiveness of other therapeutic agents and modulates the tumor microenvironment by affecting tumor‐associated macrophages (TAMs). CUR analogues, such as hydrazinocurcumin (HC), FLLL11, FLLL12, and GO‐Y030, show improved bioavailability and potency in inhibiting STAT3, resulting in reduced cell proliferation and increased apoptosis.Conclusion: CUR and its analogues hold promise as effective adjuvant treatments for BC by targeting the STAT3 signaling pathway. These compounds provide new insights into the mechanisms of action of CUR and its potential to enhance the effectiveness of BC therapies.